Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 108.00 37,961 08:00:00
Bid Price Offer Price High Price Low Price Open Price
106.00 110.00 108.00 108.00 108.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.51 -75.57 -53.80 146
Last Trade Time Trade Type Trade Size Trade Price Currency
15:21:48 O 10,000 107.20 GBX

Arix Bioscience (ARIX) Latest News

More Arix Bioscience News
Arix Bioscience Investors    Arix Bioscience Takeover Rumours

Arix Bioscience (ARIX) Discussions and Chat

Arix Bioscience Forums and Chat

Date Time Title Posts
01/10/202020:53Arix Bioscience plc152
30/7/201810:14Arix Bioscience (ARIX) One to Watch -

Add a New Thread

Arix Bioscience (ARIX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Arix Bioscience trades in real-time

Arix Bioscience (ARIX) Top Chat Posts

Arix Bioscience Daily Update: Arix Bioscience Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ARIX. The last closing price for Arix Bioscience was 108p.
Arix Bioscience Plc has a 4 week average price of 105p and a 12 week average price of 74p.
The 1 year high share price is 121p while the 1 year low share price is currently 58.50p.
There are currently 135,609,653 shares in issue and the average daily traded volume is 16,580 shares. The market capitalisation of Arix Bioscience Plc is £146,458,425.24.
bahiflyer: Looking brighter with some traction behind ARIX now Woodford well and truly gone and now another NASDAQ IPO with LogicBio. Should see the gap to NAV continue to close
escapetohome: It would seem so norbie. Great update. Really positive for the future. Im glad i found this share. Im in profit and holding.
ohisay: Presentations ...and webcast at 1230 if anybody's interested . Nav of 185p suggests overlarge disconnect with the share price especially with 32p per share cash on the balance sheet..I've added this morning .
escapetohome: Dr Naseem Amin, Executive Chairman of Arix Bioscience plc, commented: "This has been a pivotal period for Arix and our companies. We have refocused and streamlined the business, significantly reducing costs in order to maximise returns for our shareholders. Over the period our portfolio has continued to make strong progress, with a number of companies reaching important clinical milestones and completing additional financing rounds at higher valuations.
escapetohome: Net Asset Value of £251.0 million (December 2019: £202.1 million); 185p per share (December 2019: 149p); a 24% increase for the first six months of 2020 Net positive portfolio revaluation of £51.7 million[1] in the period Gross Portfolio Value of £203.4 million (December 2019: £149.2 million) £11.6 million of capital deployed into the portfolio during the period £9.1 million of capital realised during the period Cash of £44.0 million (December 2019: £54.6 million) 20% IRR generated by the Gross Portfolio since inception in 2016 ---[1] Including FXOperational and strategic progress:
cokehookerscars: SYNC is very interesting but whilst similar in some ways, each of these types of companies are quite different based upon their very specific holdings and the pipelines of those specific companies. ARIX seem to have a few more irons in the fire than SYNC so I still have high hopes for ARIX but we need to see more positive news coming out in order to have confidence things are going the right way for those things in the pipelines.
escapetohome: Took a nibble at these. A comparable outfit seems to be Syncona (SYNC) , but where that seems to have done quite well and perhaps even trades at a premium, i sense ARix trades at a heavy discount and has performed poorly. Why? Woodfords spell? They both seem to own Autolus. Might have to wait a while before they perk up.
nchanning: Have been one of the people buying . All I know is that with 54 million in cash , and c. 100£ million worth of equity investments at last count not a lot needs to go right for Arix to add another 50% from here Cutting operating expenses is absolutely the best way to realise value here . Hard to see how all these highly paid execs and entrepreneurs in residence are adding any value . Cut costs to bare bones and simply make follow on investments in companies that Arix already owns and wait to realise assets close to par is an easy way to get share price close to NAV and big win for shareholders . Needless to say a 6 month virus demandshock has a trifling effect on earlybiotech companies which are years away from generating revenue .
stevenb3: Iterium and LogicBio were both up 11% yesterday on NASDAQ. However, I don't expect this to follow through into the Arix share price.
rambutan2: Agree. Only gripe is the still too high costs. Hasn't really shifted the share price, I assume due to Woodford overhang worries, but confirms that currently on offer at a 25% discount to nav. Worth noting that at 31/12, AUTL which is easily the largest investment, closed at $32. At close on fri it was around that price, so ARIX's nav is a still valid one. Also even after post y/e fundings, by my calcs there is still well over £70m of cash on the balance sheet. LONDON, 28 March, 2019: Arix Bioscience plc (LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences, today announces its annual results for the year ended 31 December 2018. Financial highlights * GBP70m net positive revaluation of the portfolio[1] * GBP52m invested across the portfolio and a further GBP16m post year-end[2] * Gross portfolio value increased to GBP175m (2017: GBP54m) * Net Asset Value increased to GBP270m (2017: GBP146m) * GBP87m capital raise in March 2018 * NAV per share increased to GBP2.00 (2017: GBP1.52) Operational highlights * Nasdaq listing of four Arix companies[3] * Positive portfolio progression; 26 clinical trials underway; 19 expected readouts in 2019[4] * $555m capital raised by Arix portfolio companies in 2018 * New commercial partnerships added with Fosun, Ipsen and Fred Hutchinson Cancer Research Center Post period end investments: * Co-led $63m Series B for Imara, a clinical stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies; committing $15m (GBP11.3m) * Harpoon completed a successful IPO on Nasdaq, raising $81m; Arix invested $6m (GBP4.6m) to retain a stake of 12.1% Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "We are encouraged by progress in 2018 with a number of positive developments in our business, and a net increase of GBP70m in the value of our portfolio companies. Overall, we grew our Net Asset Value from GBP146m at the beginning of 2018 to GBP270m at year end which, on a per share basis, was an increase of 32% over the year. "This performance is an early sign, I believe, of the potential in our business and the strength of the young portfolio we have built. We are well positioned for further growth and investment in 2019 and look forward to the year ahead with confidence and optimism".
Arix Bioscience share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201026 22:52:14